Intuitive Surgical stock trades near record levels as robotic surgery growth supports valuation

Intuitive Surgical stock is trading near record territory on Nasdaq as investors continue to price in strong growth in robotic-assisted surgery volumes and solid profitability from the company’s Da Vinci system franchise, based on 2024 and recent quarterly results as reported by leading financial portals and the firm’s filings.

Revenue up double digits in 2024

Intuitive Surgical, Inc. (ISIN US46120E6023) reported double-digit revenue growth in fiscal 2024, with total revenue rising to roughly $7.5 billion from about $6.2 billion in 2023, according to data compiled from the company’s annual report and reputable market data services. This represents an increase of around 21% year over year, underpinned by higher procedure volumes and installed base expansion for the Da Vinci robotic surgery platform.

According to the firm’s 2024 filings and widely cited analyst summaries, instrument and accessory revenue accounted for a significant portion of the top line, increasing alongside procedural growth; systems revenue also expanded as hospitals and surgical centers added new Da Vinci units. The company’s recurring revenue model – with instruments and accessories required for each procedure – helped drive predictable cash flow as utilization increased.

Margins expand as procedures grow

Profitability improved meaningfully in 2024, with operating income rising faster than revenue. Based on aggregated figures from Intuitive Surgical’s 2024 Form 10-K and consensus data on major financial sites, the company generated operating income of roughly $2.5 billion in 2024, up from about $2.0 billion in 2023, implying growth of around 25%. This lifted the operating margin to the low-30 percent range in 2024 compared with the high-20 percent area the year before, reflecting scale benefits and cost discipline.

Net income also increased in 2024, with widely referenced figures showing profit in the region of $2.1 billion compared with about $1.7 billion in 2023, a gain of roughly 24%. Earnings per share followed a similar trajectory, supported by both higher operating earnings and the effect of share repurchases carried out over recent years, which reduced the average share count and contributed to EPS growth.

For investors, the margin profile is a central part of the Intuitive Surgical story: the combination of high gross margins on instruments and accessories and the software-like characteristics of the installed base have allowed the company to convert revenue growth into disproportionately higher profits, reinforcing the premium valuation of Intuitive Surgical stock.

Procedure volumes and installed base

Operational metrics provide another perspective on Intuitive Surgical’s growth trajectory. Industry and company data for 2024 indicate that Da Vinci procedure volumes increased by about 20% compared with 2023, reaching well above 2 million procedures worldwide from a base of around 1.7 million the previous year. This expansion was broad-based across general surgery, urology, gynecology, and other specialties, as surgeons progressively adopt minimally invasive techniques for a wider range of indications.

The installed base of Da Vinci systems also expanded materially. According to figures cited in Intuitive Surgical’s most recent annual filing and widely used investor presentations, the company had more than 8,000 systems installed globally by the end of 2024, up from roughly 7,000 units a year earlier. Growth came from both new system placements and upgrades of older systems to newer generations with enhanced capabilities, which can support higher procedure throughput.

This combination of a growing installed base and rising utilization is central to the company’s recurring revenue model. As more systems are placed and used more frequently, demand for instruments and accessories increases, supporting top-line growth even in periods when capital equipment budgets are more cautious.

Balance sheet strength and cash generation

Intuitive Surgical’s financial structure remains conservative, with the company carrying little or no long-term debt according to its latest annual filing data, while maintaining a substantial cash position. Total cash, cash equivalents, and investments at the end of 2024 were widely reported in the region of $9 billion, giving the company ample flexibility to invest in research and development, support commercial expansion, and pursue selective acquisitions without relying heavily on external financing.

Cash flow metrics reinforce this picture. Operating cash flow in 2024 has been reported by multiple financial data aggregators at above $2.5 billion, up from around $2.1 billion in 2023. This increase reflects both higher profitability and favorable working capital movements, such as efficient inventory management and receivables collection. Free cash flow remained robust after capital expenditures for manufacturing capacity, instruments, and facilities, indicating that the company continues to generate substantial cash after investments.

From an investor perspective, a strong net cash position combined with high and growing free cash flow underpins the ability to fund ongoing innovation in robotic surgery, maintain service levels for the installed base, and potentially return cash to shareholders through share repurchases or future dividends, even though the current focus is largely on reinvestment in growth.

Valuation metrics and market capitalization

Intuitive Surgical stock’s valuation is closely watched because of the company’s premium growth profile. Based on commonly cited recent market data from major financial portals, the Nasdaq-listed shares have been trading with a market capitalization in the range of $140 billion to $160 billion as of mid-2026. That represents a significant increase compared with a market cap around $110 billion to $120 billion in mid-2024, reflecting both share price appreciation and the company’s rising earnings power.

On earnings-based metrics, widely used consensus estimates suggest that Intuitive Surgical has traded at a forward price-to-earnings multiple in the mid-40s to low-50s in recent months. While this is well above the broader market’s average, many investors consider the multiple justified by the combination of secular growth in minimally invasive surgery, high margins, and a technology moat built over more than two decades.

The stock also commands a high enterprise value to EBITDA ratio relative to traditional medical device peers, as the market prices in not only current financial performance but also the potential for further adoption of robotic surgery globally. Compared with some diversified medtech groups that trade at low- to mid-teens EBITDA multiples, Intuitive Surgical’s valuation reflects its more concentrated exposure to a rapidly scaling niche.

Revenue up more than 20 percent

The increase in revenue of roughly 21% from around $6.2 billion in 2023 to approximately $7.5 billion in 2024 stands out as a key metric for assessing performance. This growth rate is well above typical single-digit expansion for many large medical device companies, highlighting Intuitive Surgical’s position at the intersection of technology and healthcare. The quantified comparison underscores that Intuitive Surgical is not only growing from a sizable base but also accelerating its top line at a rate that helps support its valuation.

Investors often compare this revenue growth with the company’s procedure volume expansion, which has been around 20% year over year based on widely cited 2024 data. The close alignment between procedure growth and revenue underscores the efficiency of Intuitive Surgical’s commercial model: more procedures translate directly into higher demand for instruments and accessories, while system placements add incremental capacity for future growth.

In this context, Intuitive Surgical’s revenue trajectory also supports research and development spending. The company has typically invested a high-single-digit to low-double-digit percentage of revenue into R&D annually, which would imply around $600 million to $800 million in R&D expenses in 2024 given the revenue figures. This investment aims to sustain technological leadership through upgrades to Da Vinci and the development of new robotic platforms.

Robotic surgery product focus

Intuitive Surgical’s core product line is the Da Vinci surgical system, a robotic platform designed to enable minimally invasive surgery across multiple specialties. The company’s 2024 reports and widely used investor materials describe Da Vinci as comprising a surgeon console, a patient-side cart with robotic arms, and high-definition imaging components, along with a range of instruments and accessories tailored to specific procedures.

Revenue from instruments and accessories – the recurring component tied to each procedure – accounted for a majority of total revenue in 2024 according to widely quoted annual report figures, exceeding 60% of the top line. Systems revenue, derived from the sale and leasing of Da Vinci units, contributed the remaining portion. This mix demonstrates the importance of the installed base and procedural growth in shaping Intuitive Surgical’s financial profile.

The company has continued to refine the Da Vinci platform, with newer generations offering enhanced capabilities such as improved ergonomics, advanced energy devices, and upgraded imaging with augmented visualization. These enhancements can support more complex procedures and broaden the addressable market. The resulting expansion in indications – from urology and gynecology into general surgery and thoracic procedures – has been a key driver of the increase in annual procedure volumes to well over 2 million by 2024.

Intuitive Surgical stock price context

While specific intraday quotes vary by the moment, Intuitive Surgical stock on Nasdaq has recently traded in a range that places it near the upper end of its 52-week band. Market data from major portals indicate that over the past year, the shares have seen a low around $250 and a high approaching $420, reflecting both broader market volatility and company-specific developments. As of mid-2026, the stock has been trading closer to the top of this historical range, supported by solid 2024 results and ongoing growth in procedure volumes.

For investors, the share price context relative to the 52-week range offers one way to gauge market sentiment. Trading near the high end of the band suggests that the market continues to view Intuitive Surgical favorably, with confidence in the sustainability of its growth drivers. However, the elevated valuation also means that expectations are high, and future earnings and procedure data will likely be scrutinized closely to ensure they justify the current pricing of Intuitive Surgical stock.